CEBPA and myeloid sarcoma: In evaluation of children with low risk AML (e.g., inv(16), t(8;21), NPM1 mutated without FLT3-ITD mutation, and CEBPA mutation), reports demonstrated worse RFS and EFS in patients with MS present compared to those without MS present [20,21,22].